F8 and hemophilia A: The hypothesis that HA patients with an intron-22 inversion (Int22Inv) mutation have a lower risk of developing a neutralizing anti-FVIII antibody (“inhibitor”) response (24, 25) has gained fairly wide traction in the hemophilia A community.